Skip to main content
Premium Trial:

Request an Annual Quote

Bioinfra, 20/20 GeneSystems Ink Deal for US Sales of Multi-Cancer Test

NEW YORK — Bioinfra Life Sciences said Thursday it had signed an exclusive licensing agreement for 20/20 GeneSystems to sell Bioinfra's technology in the US market.

Korean firm Bioinfra and Maryland-based 20/20 GeneSystems have both developed assays for the early detection of multiple cancers. Bioinfra said its test, which is available for less than $200, improves diagnostic accuracy by incorporating measures of several inflammatory biomarkers, and the results include algorithm-driven risk assessments of individual tumor types rather than overall cancer risk.

The companies said 20/20 plans to add Bioinfra's technology to a premium version of 20/20's OneTest blood-based assay for early detection of multiple cancers, and that test, anticipated to become available in Q4 2022, is expected to cost less than $300. 20/20 President and CEO Jonathan Cohen said the partnership will improve the diagnostic accuracy and clinical value of the OneTest assay.

Bioinfra will receive upfront payments and test volume-based royalties. Further details of the agreement were not disclosed.

The deal is Bioinfra's first outside Korea, and the firm is exploring opportunities in other countries, it said.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.